Page last updated: 2024-08-17

quinoxalines and (5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol

quinoxalines has been researched along with (5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bethel, K; Cullen, BR; Jin, HY; Kang, SG; Lai, M; Liu, WH; Oda, H; Rajewsky, K; Sabouri-Ghomi, M; Shepherd, J; Skalsky, RL; Xiao, C1
Cong, L; Xia, ZK; Yang, RY1
Anderson, WH; Catlow, JT; Felder, CC; Higgs, RE; Kuo, MS; Laksmanan, A; Li, X; Martin, AE; Nikolayev, A; Schober, DA; Tolstikov, VV; Witkin, JM1

Other Studies

3 other study(ies) available for quinoxalines and (5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol

ArticleYear
MicroRNA-17~92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways.
    The EMBO journal, 2013, Aug-28, Volume: 32, Issue:17

    Topics: Animals; B-Lymphocytes; Burkitt Lymphoma; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Imidazoles; Lymphoma; Mice; Mice, Inbred C57BL; Mice, Transgenic; MicroRNAs; Morpholines; NF-kappa B; Phosphatidylinositol 3-Kinases; Quinoxalines; Reproducibility of Results; RNA, Long Noncoding

2013
Targeting the TGF-β receptor with kinase inhibitors for scleroderma therapy.
    Archiv der Pharmazie, 2014, Volume: 347, Issue:9

    Topics: Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Molecular Targeted Therapy; Morpholines; Protein Binding; Protein Kinase Inhibitors; Pyrazoles; Quinolines; Quinoxalines; Receptors, Transforming Growth Factor beta; Scleroderma, Systemic

2014
Further Evaluation of Mechanisms Associated with the Antidepressantlike Signature of Scopolamine in Mice.
    CNS & neurological disorders drug targets, 2017, Volume: 16, Issue:4

    Topics: Animals; Antidepressive Agents; Citalopram; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Frontal Lobe; Ketamine; Male; Metabolome; Mice, Inbred C57BL; Mice, Knockout; Morpholines; Quinoxalines; Receptor, Muscarinic M1; Receptors, AMPA; Scopolamine; Selective Serotonin Reuptake Inhibitors; TOR Serine-Threonine Kinases

2017